Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients

In BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a second-line option is considered ineffective by many practitioners based on historical...

Descripción completa

Detalles Bibliográficos
Autores principales: Saint-Jean, Mélanie, Fronteau, Clémentine, Peuvrel, Lucie, Khammari, Amir, Varey, Emilie, Quéreux, Gaëlle, Dréno, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373626/
https://www.ncbi.nlm.nih.gov/pubmed/32702928
http://dx.doi.org/10.1097/MD.0000000000021329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373626/
https://www.ncbi.nlm.nih.gov/pubmed/32702928
http://dx.doi.org/10.1097/MD.0000000000021329

Ejemplares similares